NKGen Biotech(US:NKGN) GlobeNewswire News Roomยท2024-06-12 17:05Core Insights - The presentation by Dr. Song highlighted the potential benefits of eliminating pre-treatment lymphodepletion in patients undergoing SNK02 therapy, which may help preserve immune function and enhance recovery [1][5] - The Phase 1 clinical trial results indicated that SNK02 was well-tolerated as a monotherapy and showed clinical activity against heavily pretreated solid tumors without the need for lymphodepletion [2][6] Company Overview - NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on developing and commercializing innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics [5][9] - The company is headquartered in Santa Ana, California, and is dedicated to advancing NK cell therapies for a broad range of cancers [9] Clinical Trial Details - The Phase 1 clinical trial involved administering SNK02 intravenously on a weekly basis for a total of 8 weeks, starting with a dose of 6 x 10^9 SNK02 cells [6] - The trial enrolled 6 patients with advanced refractory solid tumors, with a median age of 64 years and an average of 4 prior lines of therapy [2] - Among the patients who completed 8 cycles of SNK02, 100% demonstrated stable disease, indicating that the tumor growth was halted [2] Safety and Efficacy - Adverse events related to the investigational product were reported, with 17 Grade 1, 3 Grade 2, and 1 Grade 3 adverse events observed, indicating a generally favorable safety profile [2][6] - The development of auto-antibodies was noted around Cycle 5, but there was no correlation with adverse events or tumor response [2] Future Directions - The company plans to further explore the efficacy of SNK02 in combination with immune checkpoint inhibitors and monoclonal antibodies for treating solid tumors [2][5]